Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-Adapted Therapy for DLBCL (E3404)
NCT00274924Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Sep 2006
- Primary completion
- Jun 2013
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of ifosfamide, carboplatin and etoposide in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Eastern Cooperative Oncology Group. Primary endpoint: Progression-Free Survival at 2 years. Started Sep 2006; status: completed.
02
Drugs
ifosfamidecarboplatinetoposide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00274924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274924.